Pasireotide treatment for severe congenital hyperinsulinism due to a homozygous ABCC8 mutation

• Main Authors: Christiaan F. Mooij (Author), Carline E. Tacke (Author), Mirjam E. van Albada (Author), Winfried Barthlen (Author), Hennie Bikker (Author), Klaus Mohnike (Author), Matthijs W.N. Oomen (Author), A.S. Paul van Trotsenburg (Author), Nitash Zwaveling-Soonawala (Author)
• Format: Book
• Published: Korean Society of Pediatric Endocrinology, 2021-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

ABCC8 and KCJN11 mutations cause the most severe diazoxide-resistant forms of congenital hyperinsulinism (CHI). Somatostatin analogues are considered as secondline treatment in diazoxide-unresponsive cases. Current treatment protocols include the first-generation somatostatin analogue octreotide, al...